Tech Session III: Nanomedicine and Nanoscale Delivery (Nano)
Sustained-Release of Novel Therapies for Treating Opioid Use Disorder
Wednesday, July 16, 2025
11:16 AM – 11:27 AM EDT
Introduction: The prevalence of Opioid Use Disorder (OUD) has reached epidemic levels, affecting 2.7 million individuals aged 12+ in the U.S. as of 2020, per the National Institute on Drug Abuse (NIDA). While Medication for OUD (MOUD), such as methadone, buprenorphine, and naltrexone, has proven effective, challenges like patient retention, frequent dosing, and side effects persist [1-2]. These issues highlight the urgent need for preclinical research to develop OUD treatments. This study aims to develop long-acting injectables (≥1 month) that are both highly efficacious and safe for treating OUD.
Learning Objectives:
At the completion of this activity, participants will know
Understand the challenges associated with current treatments for opioid use disorder (OUD).
Examine the pharmacokinetics, efficacy, and safety of the therapy in preclinical models.
